Duan Xingxiang, Wang Yang, He Jingjing, Peng Yingying, Yu Juan, Sun Yi
Institute of Reproduction and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha 410078, China.
National Engineering Research Center of Human Stem Cells, Changsha 410205, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017 Apr 28;42(4):457-462. doi: 10.11817/j.issn.1672-7347.2017.04.015.
Many risk factors lead to hypohepatia and hepatic failure, causing people suffering from end-stage liver disease. The conventional treatment for end-stage liver disease is not good enough. Orthotopic liver transplantation is effective. However, the high cost, lack of liver source, immune rejection and other factors limit the large-scale clinical application. Thus, cell therapy is a good option. Studies on common cell sources for the treatment of liver disease and the induction of hepatocytes by embryonic stem cells or pluripotent stem cells have made progress. With the development of stem cell technology, cell transplantation has become a new option, which brings hope to people with end-stage liver diseasetransplantation has become a new option. It brings hope to people with end-stage liver disease.
许多风险因素会导致肝功能减退和肝衰竭，致使人们罹患终末期肝病。终末期肝病的传统治疗效果欠佳。原位肝移植效果显著。然而，高昂的费用、肝源短缺、免疫排斥等因素限制了其大规模临床应用。因此，细胞治疗是一个不错的选择。关于治疗肝病的常见细胞来源以及胚胎干细胞或多能干细胞诱导肝细胞的研究已取得进展。随着干细胞技术的发展，细胞移植已成为一种新的选择，给终末期肝病患者带来了希望。
